 "Zydus Cadila gets USFDA nod to sell herpes viruses treatment drug")
Drug firm Zydus Cadila Wednesday said it has received final approval from the US health regulator to market Acyclovir injecion, used to treat infections caused by herpes viruses, in the US market.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Acyclovir Sodium Injection, 500 mg/10 mL and 1,000 mg/20mL single-dosevials, Cadila Healthcare said in a BSE filing.
The approved drug will be produced at the group's formulation manufacturing facility at Moriya, Ahmedabad, it added.
The group now has nearly 216 approvals from the USFDA and so far filed 330 abbreviated new drug applications (ANDAs), Cadila Healthcare said.
The stock of Cadila Healthcare was trading 1.18 per cent higher at Rs 396.90 apiece on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app